NASDAQ$PRCT
PROCEPT BioRobotics Corporation · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
PROCEPT BioRobotics reported strong revenue growth driven by increased system sales and consumables.
PROCEPT BioRobotics reported revenue of $68.2 million for Q4 2024, a 57% increase year-over-year. The company recorded a net loss of $18.9 million, improving from a loss of $27.5 million in the prior year period. Operating expenses increased due to commercial expansion and higher general and administrative costs. Gross margin improved to 64% from 49% in the prior year period.
- Revenue increased 57% to $68.2 million.
- Net loss narrowed to $18.9 million from $27.5 million.
- Gross margin improved to 64% from 49%.
- U.S. system revenue increased 67% year-over-year.
Headline financials
Revenue & EPS history
PROCEPT BioRobotics · Revenue · Quarterly
$68.2M
Revenue by segment
PROCEPT BioRobotics · $33M total across 4 segments · Q3 2023
- U.S. Consumables$17M+112.7%51.7%
- U.S. System Sales$13.5M+37.3%40.8%
- Intl. Consumables$1.65M+108.7%5.0%
- Intl. System Sales$828K+11.4%2.5%
Forward guidance
PROCEPT BioRobotics projects strong revenue growth for 2025 driven by system placements and consumables.
Tailwinds
- 2025 revenue projected to grow 42% to $320 million.
- Gross margin expected to improve to 64.5%.
- Continued expansion of commercial operations.
- Increased focus on global market penetration.
- Launch of new robotic platform to drive growth.
Headwinds
- Projected adjusted EBITDA loss of $35 million for 2025.
- Higher operating expenses anticipated.
- Dependence on consumable sales for revenue growth.
- Potential impact from supply chain issues.
- Increased competition in the surgical robotics space.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+1.3%
Avg return
Earnings day
-0.2%
Avg return
5 days after
+0.6%
Avg return
30 days after
45%
10 / 22 earnings
Positive
+40.6%
Q3 2024
Best reaction
-15.2%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +10.7% | +16.0% | +21.3% | |
| Q4 2025 | -15.2% | -5.7% | -5.3% | |
| Q3 2025 | +1.6% | -7.5% | +2.7% | |
| Q1 2025 | -5.6% | +1.1% | +3.0% | |
| Q4 2024 | +8.6% | -3.4% | -4.2% | |
| Q3 2024 | +40.6% | +34.2% | +41.5% | |
| Q2 2024 | -9.4% | -4.3% | +24.8% | |
| Q1 2024 | +16.5% | +15.9% | +25.3% | |
| Q4 2023 | +1.1% | +0.5% | +1.2% | |
| Q3 2023 | +21.7% | +22.5% | +39.5% | |
| Q2 2023 | -6.7% | -10.3% | -18.4% | |
| Q1 2023 | -15.0% | -20.1% | -10.9% | |
| Q4 2022 | +1.2% | -4.3% | -28.7% | |
| Q3 2022 | -9.9% | -8.4% | +5.8% | |
| Q2 2022 | +4.3% | +4.3% | +0.2% | |
| Q1 2022 | -5.1% | -17.9% | +19.5% | |
| Q4 2021 | +1.2% | +5.9% | +38.7% | |
| Q3 2020 | -2.2% | -4.5% | -28.0% | |
| Q4 2020 | -2.2% | -4.5% | -28.0% | |
| Q2 2021 | -2.2% | -4.5% | -28.0% | |
| Q1 2021 | -2.2% | -4.5% | -28.0% | |
| Q3 2021 | -4.4% | -3.9% | -29.6% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro